A global survey on the use of the international classification of diseases codes for metabolic dysfunction‑associated fatty liver disease

dc.authorid0000-0002-8909-2102
dc.contributor.authorZhang, Huai
dc.contributor.authorTargher, Giovanni
dc.contributor.authorByrne, Christopher D.
dc.contributor.authorKim, Seung Up
dc.contributor.authorWong, Vincent Wai-Sun
dc.contributor.authorValenti, Luca
dc.contributor.authorGlickman, Myer
dc.contributor.authorPonce, Jaime
dc.contributor.authorMantzoros, Christos S.
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorZou, Zhuo-Lin
dc.date.accessioned2024-09-24T07:00:00Z
dc.date.available2024-09-24T07:00:00Z
dc.date.issued2024
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
dc.identifier.citationZhang, H., Targher, G., Byrne, C.D. et al. (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International, 18(4), 1178–1201. https://doi.org/10.1007/s12072-024-10702-5
dc.identifier.doi10.1007/s12072-024-10702-5
dc.identifier.endpage1201
dc.identifier.issn1936-0541
dc.identifier.issn1936-0533
dc.identifier.issue4
dc.identifier.pmidPMID: 38878111
dc.identifier.scopus2-s2.0-85196002868
dc.identifier.scopusqualityQ1
dc.identifier.startpage1178
dc.identifier.urihttps://doi.org/10.1007/s12072-024-10702-5
dc.identifier.urihttps://hdl.handle.net/20.500.13055/798
dc.identifier.volume18
dc.identifier.wosWOS:001252919400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.relation.ispartofHepatology International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGlobal survey
dc.subjectICD-11
dc.subjectMAFLD
dc.titleA global survey on the use of the international classification of diseases codes for metabolic dysfunction‑associated fatty liver disease
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text
Boyut:
1.17 MB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: